UNLABELLED: Sequential antimicrobial therapy is an important part of antimicrobial stewardship and intends to improve the timeliness of switch to oral antimicrobials. The aim of this study was to assess the impact of the introduction of guidelines and criteria for switching to oral antimicrobials. SETTING: The study was conducted in a 753-bed academic hospital in Ireland. METHODS: The study was prospective and of controlled before and after design. Patients admitted under the care of a medical consultant were screened for inclusion. The study was divided into pre-intervention and post-intervention phases. Patients admitted and prescribed IV antimicrobials were enrolled into either a study group or control group. Post-intervention, the intervention to the study group consisted of application of stickers and criteria for switch to oral antimicrobial therapy to the drug chart. Pre-intervention in the study group and in both phases in the control group, conventional practice of clinical pharmacists reviewing drug charts and contacting prescribers to discuss a switch to an oral antimicrobial continued. The duration of intravenous treatment, the timeliness of switch to oral therapy, length of stay and cost savings were measured. MAIN OUTCOME MEASURE: The duration of intravenous antimicrobial therapy in the pre-intervention and post-intervention phases in both study and control groups. RESULTS: Pre-intervention, 85 courses of IV antimicrobials were prescribed to study group patients, compared to 60 in the control group. Post-intervention, there were 92 courses in the study group and 53 in the control group. The duration of IV antimicrobial treatment reduced significantly in the study group post-intervention, compared to the control group (P = 0.02). The timeliness of the switch also improved significantly in the study group post-intervention (P = 0.017). No improvement occurred in the control group. The median length of stay was not reduced post-intervention. Antimicrobial costs reduced by a mean of €6.41 in the study group post-intervention. CONCLUSION: This controlled before and after study demonstrates successful implementation of a pharmacist-led antimicrobial stewardship strategy. Duration of IV antimicrobial treatment reduced significantly and the timeliness of switch significantly improved. This study may be used as a template for the introduction of further pharmacist-led antimicrobial stewardship initiatives.
RCT Entities:
UNLABELLED: Sequential antimicrobial therapy is an important part of antimicrobial stewardship and intends to improve the timeliness of switch to oral antimicrobials. The aim of this study was to assess the impact of the introduction of guidelines and criteria for switching to oral antimicrobials. SETTING: The study was conducted in a 753-bed academic hospital in Ireland. METHODS: The study was prospective and of controlled before and after design. Patients admitted under the care of a medical consultant were screened for inclusion. The study was divided into pre-intervention and post-intervention phases. Patients admitted and prescribed IV antimicrobials were enrolled into either a study group or control group. Post-intervention, the intervention to the study group consisted of application of stickers and criteria for switch to oral antimicrobial therapy to the drug chart. Pre-intervention in the study group and in both phases in the control group, conventional practice of clinical pharmacists reviewing drug charts and contacting prescribers to discuss a switch to an oral antimicrobial continued. The duration of intravenous treatment, the timeliness of switch to oral therapy, length of stay and cost savings were measured. MAIN OUTCOME MEASURE: The duration of intravenous antimicrobial therapy in the pre-intervention and post-intervention phases in both study and control groups. RESULTS: Pre-intervention, 85 courses of IV antimicrobials were prescribed to study group patients, compared to 60 in the control group. Post-intervention, there were 92 courses in the study group and 53 in the control group. The duration of IV antimicrobial treatment reduced significantly in the study group post-intervention, compared to the control group (P = 0.02). The timeliness of the switch also improved significantly in the study group post-intervention (P = 0.017). No improvement occurred in the control group. The median length of stay was not reduced post-intervention. Antimicrobial costs reduced by a mean of €6.41 in the study group post-intervention. CONCLUSION: This controlled before and after study demonstrates successful implementation of a pharmacist-led antimicrobial stewardship strategy. Duration of IV antimicrobial treatment reduced significantly and the timeliness of switch significantly improved. This study may be used as a template for the introduction of further pharmacist-led antimicrobial stewardship initiatives.
Authors: A Castro-Guardiola; A L Viejo-Rodríguez; S Soler-Simon; A Armengou-Arxé; V Bisbe-Company; G Peñarroja-Matutano; J Bisbe-Company; F García-Bragado Journal: Am J Med Date: 2001-10-01 Impact factor: 4.965
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: Jan Jelrik Oosterheert; Marc J M Bonten; Margriet M E Schneider; Erik Buskens; Jan-Willem J Lammers; Willem M N Hustinx; Mark H H Kramer; Jan M Prins; Peter H Th J Slee; Karin Kaasjager; Andy I M Hoepelman Journal: BMJ Date: 2006-11-07
Authors: P Davey; E Brown; L Fenelon; R Finch; I Gould; G Hartman; A Holmes; C Ramsay; E Taylor; M Wilcox; P Wiffen Journal: Cochrane Database Syst Rev Date: 2005-10-19
Authors: K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern Journal: Infection Date: 2016-06 Impact factor: 3.553
Authors: R Murri; F Taccari; T Spanu; T D'Inzeo; I Mastrorosa; F Giovannenze; G Scoppettuolo; G Ventura; C Palazzolo; M Camici; S Lardo; B Fiori; M Sanguinetti; R Cauda; M Fantoni Journal: Eur J Clin Microbiol Infect Dis Date: 2017-10-19 Impact factor: 3.267
Authors: Matthew S Davies; Munro B Robertson; Stewart H A Brown; Bethan Saunders; W Stephen Waring Journal: Eur J Clin Pharmacol Date: 2012-03-06 Impact factor: 2.953
Authors: Larissa May; Sara Cosgrove; Michelle L'Archeveque; David A Talan; Perry Payne; Jeanne Jordan; Richard E Rothman Journal: Ann Emerg Med Date: 2012-11-02 Impact factor: 5.721
Authors: T Niwa; Y Shinoda; A Suzuki; T Ohmori; M Yasuda; H Ohta; A Fukao; K Kitaichi; K Matsuura; T Sugiyama; N Murakami; Y Itoh Journal: Int J Clin Pract Date: 2012-07-31 Impact factor: 2.503